AZD0865

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

GERD Without Erosive Esophagitis

Conditions

GERD Without Erosive Esophagitis

Trial Timeline

May 1, 2004 → Apr 1, 2005

NCT ID

NCT00206284

About AZD0865

AZD0865 is a phase 2 stage product being developed by AstraZeneca for GERD Without Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00206284. Target conditions include GERD Without Erosive Esophagitis.

What happened to similar drugs?

12 of 20 similar drugs in GERD Without Erosive Esophagitis were approved

Approved (12) Terminated (0) Active (8)

✅OMEZ 40 + OMEZ 80Dr. Reddy's LaboratoriesApproved

✅omeprazole+domperidone SR + omeprazoleDr. Reddy's LaboratoriesApproved

✅esomeprazole (Nexium®) + Xolaam®AstraZenecaApproved

✅EsomeprazoleAstraZenecaApproved

✅Esomeprazole (Nexium)AstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00206245	Phase 2	Completed	May 1, 2004	Mar 1, 2005	GERD With Erosive Esophagitis
NCT00206284	Phase 2	Completed	May 1, 2004	Apr 1, 2005	GERD Without Erosive Esophagitis

Competing Products

20 competing products in GERD Without Erosive Esophagitis

See all competitors

Product	Company	Stage	Hype Score
OMEZ 40 + OMEZ 80	Dr. Reddy's Laboratories	Approved	40
omeprazole+domperidone SR + omeprazole	Dr. Reddy's Laboratories	Approved	36
Rabeprazole ER + Ranitidine	Eisai	Phase 3	40
Rabeprazole sodium	Eisai	Phase 1	29
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Rabeprazole ER + Ranitidine	Eisai	Phase 3	40
Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg	Eisai	Phase 1	29
rabeprazole + rabeprazole	Eisai	Phase 3	40
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	40
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	40
ONO-8539	Ono Pharmaceutical	Phase 1	29
esomeprazole 40 mg	Johnson & Johnson	Pre-clinical	26
esomeprazole (Nexium®) + Xolaam®	AstraZeneca	Approved	43
esomeprazole	AstraZeneca	Pre-clinical	26
Esomeprazole	AstraZeneca	Approved	43
Esomeprazole	AstraZeneca	Approved	43
esomeprazole magnesium	AstraZeneca	Phase 1	29
Esomeprazole	AstraZeneca	Approved	43
Esomeprazole	AstraZeneca	Phase 3	40